Abstract:Abstract Disclosure: M. Ahn: None. S. Park: None. B. Suh: None. Background: Children and adolescents with chronic disease are at risk of developing bone fragility. In particular, low bone mineral density(BMD) is increasingly recognized in pediatric patients with glucocorticoid treated rheumatic disease. The purpose of this study was to evaluate the clinical characteristics of children and adolescents with systemic lupus erythematosus(SLE), and to analyze the factors associated with a lower BMD in these patients. Methods: Children and adolescents diagnosed with SLE who had received GC treatment were included. Clinical and laboratory data including anthropometry, GC exposure, other anti-rheumatic drug treatment, biochemical markers related to bone metabolism, serologic markers of disease activity in SLE, lateral thoracolumbar(D-L) spine radiography, and BMD were collected. Lumbar spine bone mineral density (LSBMD) was measured by Dual-energy x-ray absorptiometry(DXA). The correlation between BMD and anthropometry, steroid and anti-rheumatic treatment, biochemical variables was investigated. Results: A total of 30 patients with median age of 17.5 years (range 12 -25years) were included. Of the 29 patients who had DXA done, 7 patients had LSBMD z score lower than −2.0, and diagnosed as osteoporosis. SLE patients with osteoporosis were compared with those with a z score higher than −2.0. These patients had longer GC exposure, higher cumulative GC dose, longer hydroxychloroquine exposure. The main factor correlated with a low BMD was duration of GC exposure. BMD was positively correlated with height at diagnosis. Bone metabolic markers and serologic markers of disease activity in SLE had no significant correlation with BMD. Conclusion: Children and adolescent SLE patients with OP had longer GC exposure, higher cumulative GC dose compared with those with LSBMD z score higher than −2.0. The main factor correlated with a low BMD was duration of GC exposure. Therefore, efforts should be made to reduce the duration of GC exposure and reduce medication to the lower possible maintenance dose. Since longer treatment duration affects BMD, close monitoring during the treatment period is recommended to prevent further loss of bone mass in pediatric SLE patients. Presentation: Thursday, June 15, 2023

Bone mineral density determinants in adolescents and young adults with congenital adrenal hyperplasia

Cardiovascular dysfunction risk in young adults with congenital adrenal hyperplasia caused by 21-hydroxylase enzyme deficiency

Cardiovascular and Metabolic Outcomes in Congenital Adrenal Hyperplasia: A Systematic Review and Meta-Analysis

Clinical and Hormonal Profile of Classical 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia: Experience from a Tertiary Centre In India

Effect of androgen excess and glucocorticoid exposure on metabolic risk profiles in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency

Follow-up of 68 children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency: relevance of genotype for management

Endocrine, cardiac and neuropsychological aspects of adult congenital adrenal hyperplasia

Anthropometric Measures Among Children and Teens With Classic 46,XX Congenital Adrenal Hyperplasia in Relation to Improvements in Diagnosis and Care

Body composition in children and adolescents with non-classic congenital adrenal hyperplasia and the risk for components of metabolic syndrome: An observational study

THU420 Analysis Of Factors Affecting Bone Mineral Density In Children And Adolescents With Systemic Lupus Erythematosus

Factors affecting bone mineral density in children and adolescents with secondary osteoporosis

Current and novel treatment strategies in children with congenital adrenal hyperplasia

Long-term cardio-metabolic outcomes in patients with classical congenital adrenal hyperplasia: is the risk real?

Bone Microarchitecture and Volumetric Bone Density Impairment in Young Male Adults with Childhood-Onset Growth Hormone Deficiency

Cardiometabolic Aspects of Congenital Adrenal Hyperplasia

HemoglobinA1c is a Risk Factor for Changes of Bone Mineral Density: A Mendelian Randomization Study

The natural course of bone mineral density in transgender youth before medical treatment; a cross sectional study

Abstract 29: Effect of gonadotropin releasing hormone analog treatment on final adult height in children with congenital adrenal hyperplasia complicated by central precocious puberty

Near-Final Height in 82 Chinese Patients with Congenital Adrenal Hyperplasia Due to Classic 21-Hydroxylase Deficiency: A Single-Center Study from China

Bone density and bone health alteration in boys with Duchenne Muscular Dystrophy: a prospective observational study

Sex and age do not modify the association between glucocorticoids and bone mineral density in patients with rheumatoid arthritis: a cross-sectional study